1. Home
  2. KOP vs ABUS Comparison

KOP vs ABUS Comparison

Compare KOP & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KOP
  • ABUS
  • Stock Information
  • Founded
  • KOP 1988
  • ABUS 2005
  • Country
  • KOP United States
  • ABUS United States
  • Employees
  • KOP N/A
  • ABUS N/A
  • Industry
  • KOP Forest Products
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • KOP Basic Materials
  • ABUS Health Care
  • Exchange
  • KOP Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • KOP 654.9M
  • ABUS 685.7M
  • IPO Year
  • KOP 2006
  • ABUS N/A
  • Fundamental
  • Price
  • KOP $31.75
  • ABUS $3.20
  • Analyst Decision
  • KOP Buy
  • ABUS Strong Buy
  • Analyst Count
  • KOP 1
  • ABUS 4
  • Target Price
  • KOP $64.00
  • ABUS $5.50
  • AVG Volume (30 Days)
  • KOP 113.6K
  • ABUS 677.7K
  • Earning Date
  • KOP 08-07-2025
  • ABUS 07-31-2025
  • Dividend Yield
  • KOP 1.01%
  • ABUS N/A
  • EPS Growth
  • KOP N/A
  • ABUS N/A
  • EPS
  • KOP 1.22
  • ABUS N/A
  • Revenue
  • KOP $2,051,000,000.00
  • ABUS $6,403,000.00
  • Revenue This Year
  • KOP N/A
  • ABUS $3.35
  • Revenue Next Year
  • KOP $2.61
  • ABUS N/A
  • P/E Ratio
  • KOP $25.96
  • ABUS N/A
  • Revenue Growth
  • KOP N/A
  • ABUS N/A
  • 52 Week Low
  • KOP $22.99
  • ABUS $2.71
  • 52 Week High
  • KOP $41.64
  • ABUS $4.73
  • Technical
  • Relative Strength Index (RSI)
  • KOP 55.01
  • ABUS 37.60
  • Support Level
  • KOP $30.79
  • ABUS $3.29
  • Resistance Level
  • KOP $32.53
  • ABUS $3.65
  • Average True Range (ATR)
  • KOP 0.71
  • ABUS 0.13
  • MACD
  • KOP -0.22
  • ABUS -0.03
  • Stochastic Oscillator
  • KOP 34.41
  • ABUS 14.29

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: